A Single Site, Randomized, Double-blind, Placebo-controlled Phase Ib Study, to Evaluate the Chemoprotective Activity of a Single Dose of MMV390048 in a Controlled P. Falciparum Sporozoite Infection Model in Non-immune Healthy Volunteers

Trial Profile

A Single Site, Randomized, Double-blind, Placebo-controlled Phase Ib Study, to Evaluate the Chemoprotective Activity of a Single Dose of MMV390048 in a Controlled P. Falciparum Sporozoite Infection Model in Non-immune Healthy Volunteers

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs MMV 390048 (Primary)
  • Indications Falciparum malaria
  • Focus First in man; Pharmacodynamics
  • Most Recent Events

    • 01 Feb 2018 Status changed from suspended to withdrawn prior to enrolment.
    • 13 Dec 2017 Status changed from not yet recruiting to suspended.
    • 27 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top